U.S. MARKETS FOR ORTHOPEDIC BIOLOGIC AND TISSUE ENGINEERED PRODUCTS

116 Pages | 27 Exhibits | 2015 Analysis | Forecasts Through 2019

OVERVIEW:
Biologics and cellular therapies for musculoskeletal injuries-including hard tissue (i.e., bone) and soft tissue (i.e., cartilage, ligaments, and tendons)-represent a billion dollar market that is showing the potential for continued growth. Over the forecast period covered in this report, the estimated value of the U.S. market for orthopedic biologic and tissue engineered products is expected to grow by approximately $984.4 million at a compound annual growth rate (CAGR) of 8.2%; of this holistic market, biologic and cellular therapies for hard musculoskeletal tissue are forecasted to grow at a CAGR of 7.2%, while soft musculoskeletal tissue products will grow at a CAGR of 10.6%.

This report will cover:
•    Emerging and existing cellular therapies for hard and soft musculoskeletal tissue repair and regeneration;
•    Key factors influencing the growth of individual product markets;
•    Estimated market shares and sales among major U.S. suppliers
•    Companies and biotech firms developing novel cellular therapies; and,
•    Major supplier product portfolio analysis in individual product markets.

The scope of the analysis of this report covers companies developing and distributing biologics and novel cellular therapeutics for the treatment of musculoskeletal injuries. Hard tissue musculoskeletal products covered in this report include bone allograft and machined bone, demineralized bone matrix, growth factor-based bone grafts, cellular bone matrices, and select other biologics. Soft tissue musculoskeletal products covered by this report include cartilage regeneration and repair products, ligament and tendon repair technologies, and meniscus repair and regeneration products.

TABLE OF CONTENTS:
EXECUTIVE SUMMARY

i. Methodology

Exhibit ES-1: 2014, U.S. Orthopedic Biologic and Tissue Engineered Products Market, Share by Products

1. OVERVIEW OF MUSCULOSKELETAL DISEASES/DISORDERS

1.1 Back Pain and Spine Surgery
1.2 Carpal Tunnel Syndrome
1.3 Duchenne Muscular Dystrophy
1.4 Osteoarthritis
1.5 Osteoporosis and Fractures
1.6 Rheumatoid Arthritis

Exhibit 1-1: Musculoskeletal Surgery, Procedure Volumes Forecast, by Type, 2014-2019

2. U.S. MARKETS FOR BIOLOGIC MUSCULOSKELETAL SOFT TISSUE REGENERATION AND REPAIR PRODUCTS

2.1 Cartilage Regeneration and Repair Technologies
	2.1.1 Currently Available Products
		2.1.1.1 Arthrex
		2.1.1.2 Vericel
		2.1.1.3 Zimmer
	2.1.2 Products in Development
		2.1.2.1 CellCoTec
		2.1.2.2 Cytori Therapeutics
		2.1.2.3 Histogenics
		2.1.2.4 ISTO Technologies
		2.1.2.5 Medipost
		2.1.2.6 TETEC
		2.1.2.7 TiGenix
		2.1.2.8 TissueGene
	2.1.3 Market Forecast
	2.1.4 Competitive Analysis
2.2 Ligament and Tendon Repair Technologies
	2.2.1 Graft-Based Products Overview
	2.2.2 Tissue Engineering
		2.2.2.1 Biologic Scaffolds 
		2.2.2.2 Developmental Biologic Scaffolds
	2.2.3 Market Forecast
	2.2.4 Competitive Analysis
2.3 Meniscus Repair and Regeneration Technologies
	2.3.1 Products Overview
	2.3.2 Market Forecast
	2.3.3 Competitive Analysis
	2.2.4 U.S. Markets for Biologic Soft Tissue Regeneration and Repair Products

Exhibit 2-1: 2014, Cartilage Repair Procedures
Exhibit 2-2: Cartilage Repair and Regeneration Products, Market Forecast, 2014-2019
Exhibit 2-3: 2014, Knee Cartilage Repair and Regeneration Products Market, Share by Supplier
Exhibit 2-4: 2015, Selected Allografts for Ligament and Tendon Replacement
Exhibit 2-5: 2015, Biologic Scaffolds and Matrices for Ligament and Tendon Repair
Exhibit 2-6: Ligament and Tendon Replacement and Regeneration Products, Market Forecast, 2014-2019
Exhibit 2-7: 2014, Ligament and Tendon Replacement and Regeneration Products Market, Share by Supplier
Exhibit 2-8: 2015, Selected Biologic Meniscal Repair Products
Exhibit 2-9: Meniscal Replacement and Regeneration Products, Market Forecast, 2014-2019
Exhibit 2-10: 2014, Meniscal Replacement and Regeneration Products Market, Share by Supplier
Exhibit 2-11: Musculoskeletal Soft Tissue Biologics Products, Market Forecast, 2014-2019

3. U.S. MARKETS FOR BIOLOGIC MUSCULOSKELETAL HARD TISSUE REGENERATION AND REPAIR

3.1 Bone Graft and Bone Substitute Products on the Market and Under Development
	3.1.1 Bone Autograft
	3.1.2 Bone Allografts and Machined Bone
	3.1.3 Demineralized Bone Matrix
	3.1.4 Market Forecast
	3.1.5 Competitive Analysis
3.2 Growth Factor-Based Bone Grafts
	3.2.1 Products Overview
		3.2.1.1 Bioventus
		3.2.1.2 Medtronic
		3.2.1.3 Wright Medical Technology
	3.2.2 Market Forecast
	3.2.3 Competitive Analysis
3.3 Other Biologics Currently Available or in Development
	3.3.1 Cellular Bone Matrices
		3.3.1.1 AlloSource
		3.3.1.2 Biomet
		3.3.1.3 NuVasive
		3.3.1.4 Orthofix
		3.3.1.5 Osiris Therapeutics
		3.3.1.6 RTI Surgical
	3.3.2 Cellular Regeneration Therapies in Development for Hard Bone Musculoskeletal Repair
		3.3.2.1 Cerapedics, Inc.
		3.3.2.2 Ferring Pharmaceuticals
		3.3.2.3 Mesoblast
	3.3.3 Market Forecast
	3.3.4 Competitive Analysis
3.4 Emerging Areas of Cellular Therapy for Soft and Hard Tissue Repair and Regeneration
	3.4.1 Bone Marrow Aspirate Concentrate
	3.4.2 Gene Therapy
		3.4.2.1 Systemic Gene Therapy
		3.4.2.2 Regional Gene Therapy
	3.4.3 Three-Dimensional Printing
3.5 U.S. Markets for Musculoskeletal Hard Tissue Regeneration and Repair Products
3.6 Combined Market Summary for Hard and Soft Tissue Engineering and Cellular Therapy Products

Exhibit 3-1: 2015, Description and Representative Pricing of Base Allografts Used in Spine Surgery
Exhibit 3-2: 2015, Selected Bone Allograft and Machined Bone Products
Exhibit 3-3: 2015, Selected Demineralized Bone Matrix Products
Exhibit 3-4: Bone Allografts and Synthetic Bone Graft Substitutes, Market Forecast, 2014-2019
Exhibit 3-5: 2014, Bone Allograft Products Market, Share by Supplier
Exhibit 3-6: 2014, Demineralized Bone Matrix Products Market, Share by Supplier
Exhibit 3-7: Growth Factor-Based Products, Market Forecast, 2014-2019
Exhibit 3-8: 2014, Growth Factor-Based Products Market, Share by Supplier
Exhibit 3-9: Stem Cell Matrices and Other Osteobiologic Agents for Bone Healing and Enhancement of Spinal Fusion, Market Forecast, 2014-2019
Exhibit 3-10: 2014, Market Shares of Stem Cell Applications for  Bone Healing and Spinal Fusion by Application
Exhibit 3-11: 2014, Stem Cell Products and Other Orthobiologics for Bone 
Healing and Spinal Fusion, Share by Supplier
Exhibit 3-12: U.S. Biologic Products for Musculoskeletal Hard Tissue Repair and Regeneration, Combined Market Forecast, 2014-2019
Exhibit 3-13: U.S. Hard and Soft Musculoskeletal Tissue Repair and Regeneration, Combined Procedure Volumes, 2014-2019
Exhibit 3-14: U.S. Biologic Products for Musculoskeletal Hard and Soft Tissue Repair and Regeneration, Combined Market Forecast, 2014-2019

APPENDIX:  COMPANY LISTING

BIBLIOGRAPHY


COMPANIES COVERED:

  1. Aesculap Implant Systems/B. Braun Melsungen
  2. AlloSource
  3. Alphatec Spine
  4. Arthrex
  5. B. Braun Melsungen
  6. Bacterin/Bacterin International
  7. Biomet
  8. Bioventus
  9. CellCoTec
  10. Cerapedics, Inc.
  11. Collagen Matrix
  12. ConMed Linvatec/ConMed
  13. Cytori Therapeutics
  14. DePuy Synthes/Johnson & Johnson
  15. Exactech
  16. Ferring Pharmaceuticals
  17. Globus Medical
  18. Histogenics
  19. Integra LifeSciences
  20. ISTO Technologies
  21. Johnson & Johnson
  22. JRF Ortho
  23. K2M
  24. LifeCell/Acelity
  25. LifeLink Tissue Bank
  26. LifeNet Health
  27. Medipost
  28. Medtronic
  29. Mesoblast
  30. MiMedx
  31. Musculoskeletal Transplant Foundation
  32. NuVasive
  33. Orthocell
  34. Orthofix
  35. Osiris Therapeutics
  36. RTI Surgical
  37. Stryker
  38. TEI Biosciences
  39. TiGenix
  40. Tissue Engineering Technologies (TETEC)/B. Braun Melsungen
  41. TissueGene
  42. Tornier
  43. Vericel
  44. Wright Medical Technology
  45. Zimmer
Contact Us

Need help finding medtech research? Let us help you!